Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Digital Pathology Partnership Integrates Breast Cancer Diagnostic and Prognostic Tools

By LabMedica International staff writers
Posted on 15 Sep 2026

Breast cancer diagnostics rely on reproducible histological grading and timely interpretation of immunohistochemical biomarkers to guide therapy. More...

Access to prognostic risk profiling can be limited by long turnaround times and the expense of gene expression testing, which can constrain use. A new partnership now links AI-based diagnostic and prognostic tools in a single digital workflow to address these challenges.

Aiforia (Helsinki, Finland) and Stratipath (Solna, Sweden) have formed a strategic collaboration to integrate the Stratipath Breast solution into the Aiforia Clinical Platform. The integration will allow laboratories to access both companies’ breast cancer AI applications through one streamlined workflow. The partners also plan joint go‑to‑market initiatives to broaden adoption among cancer care centers worldwide.

Aiforia Breast Cancer Suite provides a fully digital cockpit for breast cancer diagnostics, supporting the entire diagnostic workflow. The suite assists pathologists with histological grading consistent with the Nottingham Grading System and with assessment of estrogen receptor (ER), progesterone receptor (PR), Ki67, and human epidermal growth factor receptor 2 (HER2) immunohistochemistry. Stratipath Breast is an AI-based prognostic risk‑profiling tool that analyzes cancer tissue to identify patients at increased or low risk of disease progression; it is already in clinical use and has been validated in large‑scale studies.

Regulatory alignment is specified for each solution. Aiforia Breast Cancer Suite is CE-IVD marked for diagnostic use in Europe and the European Economic Area. Stratipath Breast is aligned with regulatory requirements for clinical use in the European Union and the United Kingdom, and AI-based risk stratification enables faster turnaround times, provides new information at the point of diagnosis, and can reduce the need for expensive gene expression testing, allowing wider use and benefit to more patients.

“Stratipath Breast is an ideal addition to Aiforia’s Breast Cancer Suite, the most comprehensive diagnostic AI-solution in the industry for breast cancer diagnostics. Combining our solutions gives pathologists and oncologists faster access to validated, high-impact AI tools within a workflow they already trust. We look forward to our collaboration with Stratipath,” said Jukka Tapaninen, CEO of Aiforia.

“Behind every tissue sample is a person waiting to find out how aggressive their cancer is. Together with Aiforia, we bring risk profiling to more hospitals, delivering results in minutes rather than weeks. Precision diagnostics should be standard of care, not a privilege, and this partnership takes us a step closer,” said Fredrik Wetterhall, CEO and co-founder of Stratipath.

Related Links
Aiforia
Stratipath


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.